ANI Pharmaceuticals Inc (ANIP)
66.43
+0.43
(+0.65%)
USD |
NASDAQ |
May 01, 16:00
66.53
+0.10
(+0.15%)
Pre-Market: 20:00
ANI Pharmaceuticals Cash from Financing (Quarterly): -11.92M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -11.92M |
| September 30, 2023 | 3.755M |
| June 30, 2023 | 80.15M |
| March 31, 2023 | -4.548M |
| December 31, 2022 | -0.508M |
| September 30, 2022 | -0.911M |
| June 30, 2022 | -1.437M |
| March 31, 2022 | -2.27M |
| December 31, 2021 | 179.44M |
| September 30, 2021 | -3.022M |
| June 30, 2021 | 20.90M |
| March 31, 2021 | -2.725M |
| December 31, 2020 | -2.208M |
| September 30, 2020 | -2.378M |
| June 30, 2020 | -10.74M |
| March 31, 2020 | 13.89M |
| December 31, 2019 | -0.766M |
| September 30, 2019 | -0.77M |
| June 30, 2019 | 1.58M |
| March 31, 2019 | 1.206M |
| December 31, 2018 | -27.95M |
| September 30, 2018 | -0.731M |
| June 30, 2018 | 0.691M |
| March 31, 2018 | 0.17M |
| December 31, 2017 | 47.42M |
| Date | Value |
|---|---|
| September 30, 2017 | -4.94M |
| June 30, 2017 | -0.153M |
| March 31, 2017 | 30.02M |
| December 31, 2016 | 0.518M |
| September 30, 2016 | 1.146M |
| June 30, 2016 | -0.038M |
| March 31, 2016 | -2.355M |
| December 31, 2015 | 0.174M |
| September 30, 2015 | 0.714M |
| June 30, 2015 | 0.16M |
| March 31, 2015 | 0.018M |
| December 31, 2014 | 123.58M |
| September 30, 2014 | 0.458M |
| June 30, 2014 | -0.113M |
| March 31, 2014 | 47.72M |
| December 31, 2013 | 0.809M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | -4.498M |
| March 31, 2013 | |
| December 31, 2012 | -0.0079M |
| September 30, 2012 | 3.480M |
| June 30, 2012 | -0.0007M |
| March 31, 2012 | |
| December 31, 2011 | -1.375M |
| September 30, 2011 | 45.16M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.92M
Minimum
Dec 2023
179.44M
Maximum
Dec 2021
13.45M
Average
-0.911M
Median
Sep 2022
Cash from Financing (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 5.315M |
| ADMA Biologics Inc | -38.99M |
| Dentsply Sirona Inc | -128.00M |
| Allogene Therapeutics Inc | 0.155M |
| Vanda Pharmaceuticals Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 44.74M |
| Cash from Investing (Quarterly) | -4.779M |
| Free Cash Flow | 100.45M |
| Free Cash Flow Per Share (Quarterly) | 2.070 |
| Free Cash Flow to Equity (Quarterly) | 40.17M |
| Free Cash Flow to Firm (Quarterly) | 46.97M |
| Free Cash Flow Yield | 8.31% |